Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of throm- bosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e531S 575. CLINICAL STATEMENTS AND GUIDELINES S6.1.1-4. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131 6. S6.1.1-5. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardio- version and atrial fibrillation ablation in patients treated with riva- roxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61:1998 2006. S6.1.1-6. Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixa- ban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63:1082 7. S6.1.1-7. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346 55. S6.1.1-8. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxa- parin-warfarin in patients undergoing cardioversion of atrial fibrilla- tion (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388:1995 2003. S6.1.1-9. Pallisgaard JL, Lindhardt TB, Hansen ML, et al. Cardioversion and risk of adverse events with dabigatran versus warfarin a nation- wide cohort study. PLoS ONE. 2015;10:e0141377. S6.1.1-10. Plitt A, Ezekowitz MD, De Caterina R, et al. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016;39:345 6. S6.1.1-11. Dentali F, Botto GL, Gianni M, et al. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibril- lation: a systematic review and meta-analysis of the literature. Int J Cardiol. 2015;185:72 7. S6.1.1-12. Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. 